---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-068545"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2023-03-13T23:59:59+00:00"
generated_at: "2026-06-18T04:40:40.454036+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Acrivon reports $169.6M cash, runway into Q4 2024; ACR-368 OncoSignature enriches ORR to 47-58% in ovarian cancer

## Summary
- Cash and marketable securities $169.6M as of Dec 31, 2022 (preliminary, unaudited); projected runway into at least Q4 2024.
- ACR-368 OncoSignature test enriched ORR to 47% (NCI) and 58% (Lilly) in blinded studies of platinum-resistant ovarian cancer biopsies.
- Registrational-intent Phase 2 single-arm trials of ACR-368 monotherapy in OncoSignature-positive patients planned for ovarian, endometrial, bladder, and HPV SCC cancers.
- Internal WEE1 and PKMYT1 inhibitors advancing to IND-enabling studies in 2023.
- Past Phase 2 all-comer ORR for ACR-368 in platinum-resistant ovarian cancer was 12.1%; mDoR 5.6 months.

## SEC filing metadata
- accession: 0001193125-23-068545
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2023-03-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000119312523068545/0001193125-23-068545-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000119312523068545/d385129d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-068545
- JSON: https://secwatch.observer/filing/0001193125-23-068545.json
- Plain text: https://secwatch.observer/filing/0001193125-23-068545.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.